FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891846602> ?p ?o ?g. }

• W2891846602 endingPage "113" @default.
• W2891846602 startingPage "108" @default.
• W2891846602 abstract "To evaluate the efficacy and safety of secukinumab in Behçet's patients with active mucocutaneous and articular manifestations refractory to previous treatments.We retrospectively evaluated 5 patients treated with the IL17-inhibitor secukinumab and diagnosed with Behçet according to ISG/ICBD criteria. All patients had active mucocutaneous and articular manifestations refractory to colchicine, conventional DMARDs and at least one anti-TNFα agent. Four patients received secukinumab in the dose of 150 mg/monthly since also fulfilling the criteria for ankylosing spondylitis, while the fifth patient received secukinumab 300 mg/monthly because she met psoriatic arthritis criteria. Achievement of response was based on the number of oral ulcers, BASDAI and ASDAS for articular involvement, and BDCAF for Behçet activity. Complete response was defined as: i) decrease ≥50% in the number of oral ulcers; ii) BASDAI index <4; iii) ASDAS index <1.4; iv) decrease of 50% or more in BDCAF index.The patient starting secukinumab 300 mg/month successfully achieved complete response within 3 months. Complete response was maintained during all 9-months follow-up. Among the 4 subjects starting secukinumab 150 mg/month, two achieved complete response at month 6, but one relapsed. This patient and the two who not achieved complete response at month 6 were switched to secukinumab 300 mg/month. Within 3 months from the dosage increase, all three subjects successfully (re)achieved complete response.Our study suggested for the first time that secukinumab (either 150 mg and 300 mg/month) improved active mucocutaneous manifestations refractory to previous treatments, while secukinumab 300 mg/monthly resulted superior in inducing articular and complete response in Behçet's patients." @default.
• W2891846602 created "2018-09-27" @default.
• W2891846602 creator A5001496511 @default.
• W2891846602 creator A5035630918 @default.
• W2891846602 creator A5044432648 @default.
• W2891846602 creator A5066642738 @default.
• W2891846602 creator A5018208709 @default.
• W2891846602 creator A5030832325 @default.
• W2891846602 date "2019-02-01" @default.
• W2891846602 modified "2023-10-16" @default.
• W2891846602 title "Efficacy of the anti-IL 17 secukinumab in refractory Behçet's syndrome: A preliminary study" @default.
• W2891846602 cites W1906201952 @default.
• W2891846602 cites W1935617463 @default.
• W2891846602 cites W1998677128 @default.
• W2891846602 cites W2004943888 @default.
• W2891846602 cites W2043198160 @default.
• W2891846602 cites W2067756921 @default.
• W2891846602 cites W2103524303 @default.
• W2891846602 cites W2124257367 @default.
• W2891846602 cites W2125611737 @default.
• W2891846602 cites W2238339241 @default.
• W2891846602 cites W2278932593 @default.
• W2891846602 cites W2339070443 @default.
• W2891846602 cites W2369620788 @default.
• W2891846602 cites W2468292666 @default.
• W2891846602 cites W2509677490 @default.
• W2891846602 cites W259539928 @default.
• W2891846602 cites W2610900789 @default.
• W2891846602 cites W2621301955 @default.
• W2891846602 cites W2780640950 @default.
• W2891846602 cites W2781701627 @default.
• W2891846602 cites W2804866854 @default.
• W2891846602 doi "https://doi.org/10.1016/j.jaut.2018.09.002" @default.
• W2891846602 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30213443" @default.
• W2891846602 hasPublicationYear "2019" @default.
• W2891846602 type Work @default.
• W2891846602 sameAs 2891846602 @default.
• W2891846602 citedByCount "46" @default.
• W2891846602 countsByYear W28918466022019 @default.
• W2891846602 countsByYear W28918466022020 @default.
• W2891846602 countsByYear W28918466022021 @default.
• W2891846602 countsByYear W28918466022022 @default.
• W2891846602 countsByYear W28918466022023 @default.
• W2891846602 crossrefType "journal-article" @default.
• W2891846602 hasAuthorship W2891846602A5001496511 @default.
• W2891846602 hasAuthorship W2891846602A5018208709 @default.
• W2891846602 hasAuthorship W2891846602A5030832325 @default.
• W2891846602 hasAuthorship W2891846602A5035630918 @default.
• W2891846602 hasAuthorship W2891846602A5044432648 @default.
• W2891846602 hasAuthorship W2891846602A5066642738 @default.
• W2891846602 hasConcept C121332964 @default.
• W2891846602 hasConcept C126322002 @default.
• W2891846602 hasConcept C141071460 @default.
• W2891846602 hasConcept C142424586 @default.
• W2891846602 hasConcept C156662089 @default.
• W2891846602 hasConcept C16005928 @default.
• W2891846602 hasConcept C2776260265 @default.
• W2891846602 hasConcept C2777011040 @default.
• W2891846602 hasConcept C2777402515 @default.
• W2891846602 hasConcept C2779134260 @default.
• W2891846602 hasConcept C2779786854 @default.
• W2891846602 hasConcept C2780564577 @default.
• W2891846602 hasConcept C71924100 @default.
• W2891846602 hasConcept C87355193 @default.
• W2891846602 hasConcept C90924648 @default.
• W2891846602 hasConceptScore W2891846602C121332964 @default.
• W2891846602 hasConceptScore W2891846602C126322002 @default.
• W2891846602 hasConceptScore W2891846602C141071460 @default.
• W2891846602 hasConceptScore W2891846602C142424586 @default.
• W2891846602 hasConceptScore W2891846602C156662089 @default.
• W2891846602 hasConceptScore W2891846602C16005928 @default.
• W2891846602 hasConceptScore W2891846602C2776260265 @default.
• W2891846602 hasConceptScore W2891846602C2777011040 @default.
• W2891846602 hasConceptScore W2891846602C2777402515 @default.
• W2891846602 hasConceptScore W2891846602C2779134260 @default.
• W2891846602 hasConceptScore W2891846602C2779786854 @default.
• W2891846602 hasConceptScore W2891846602C2780564577 @default.
• W2891846602 hasConceptScore W2891846602C71924100 @default.
• W2891846602 hasConceptScore W2891846602C87355193 @default.
• W2891846602 hasConceptScore W2891846602C90924648 @default.
• W2891846602 hasLocation W28918466021 @default.
• W2891846602 hasLocation W28918466022 @default.
• W2891846602 hasOpenAccess W2891846602 @default.
• W2891846602 hasPrimaryLocation W28918466021 @default.
• W2891846602 hasRelatedWork W2891846602 @default.
• W2891846602 hasRelatedWork W2895404113 @default.
• W2891846602 hasRelatedWork W2949137526 @default.
• W2891846602 hasRelatedWork W2952362332 @default.
• W2891846602 hasRelatedWork W3193536147 @default.
• W2891846602 hasRelatedWork W4226058082 @default.
• W2891846602 hasRelatedWork W4245313846 @default.
• W2891846602 hasRelatedWork W4282559719 @default.
• W2891846602 hasRelatedWork W4283692022 @default.
• W2891846602 hasRelatedWork W4283811550 @default.
• W2891846602 hasVolume "97" @default.
• W2891846602 isParatext "false" @default.
• W2891846602 isRetracted "false" @default.
• W2891846602 magId "2891846602" @default.

• next